Company: SWKH
Filing Date: 2025-04-29
Form Type: ARS
Source: 0001628280-25-020753
Chunk: 42

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ARS
Chunk 42
---
, we entered into an exclusive Option and Asset Purchase Agreement with a strategic partner on March 14, 2024, which granted the strategic partner an exclusive option to acquire certain of Enteris’ assets related to its business of providing good manufacturing practice (GMP) manufacturing and clinical supply services through Phase 1 and 2 to third parties, subject to certain exclusions. The strategic partner must exercise the Option by or before January 1, 2026. As of December 31, 2024, Enteris is classified as held for sale as the Option is expected to be exercised within the next 12-months. Please refer to Part II, Item 8, Financial Statements , Note 13 and Note 7 of the notes to the consolidated financial statements for further information regarding the Option and Asset Purchase Agreement with the strategic partner and held for sale classification.

### Finance Receivables Portfolio Overview
The tables below provide an overview of our outstanding transactions as of, and for the year ended, December 31, 2024 (in thousands, except rate, share and per share data):

| Royalty Purchases             |     | Licensed Technology                     |     | Funded Amount |        |     | GAAP Balance |        |     | Revenue Recognized |       |
|:------------------------------|:----|:----------------------------------------|:----|:--------------|-------:|:----|:-------------|-------:|:----|:-------------------|------:|
| Besivance®(1)                 |     | Ophthalmic antibiotic                   |     | $             |  6,000 |     | $            |      — |     | $                  |    29 |
| Best ABT, Inc.(2), (3)        |     | Oncology diagnosis                      |     |               |  5,784 |     |              |  2,347 |     |                    |     — |
| Coflex®/Kybella®              |     | Spinal stenosis/submental fullness      |     |               |  4,350 |     |              |  3,053 |     |                    |   246 |
| Cambia®(4)                    |     | NSAID migraine treatment                |     |               |  8,500 |     |              |      — |     |                    |   420 |
| Duo Royalty                   |     | Japanese Women's health/cystic fibrosis |     |               | 15,